Titanium(IV) compounds are excellent anticancer drug candidates, but they have yet to find success in clinical applications. A major limitation in developing further compounds has been a general lack of understanding of the mechanism governing their bioactivity. To determine factors necessary for bioactivity, we tested the cytotoxicity of different ligand compounds in conjunction with speciation studies and mass spectrometry bioavailability measurements. These studies demonstrated that the Ti(IV) compound of N, N′-di(o-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid (HBED) is cytotoxic to A549 lung cancer cells, unlike those of citrate and naphthalene-2,3-diolate. Although serum proteins are implicated in the activity of Ti(IV) compounds, we found that these interactions do not play a role in [TiO(HBED)]
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− activity. Subsequent compound characterization revealed ligand properties necessary for activity. These findings establish the importance of the ligand in the bioactivity of Ti(IV) compounds, provides insights for developing next-generation Ti(IV) anticancer compounds, and reveal [TiO (HBED)]
− as a unique candidate anticancer compound.
drug delivery | transferrin | albumin | metal-based anticancer compounds T itanium(IV) compounds are promising candidates in the search for highly potent anticancer agents with a wide spectrum of activity. Interest in these compounds dates back to the 1970s soon after the serendipitous and revolutionary discovery of cisplatin (1), a platinum-based anticancer drug. Today platinumbased compounds are one of the major anticancer drugs on the market, but there exists a high demand for alternatives with fewer side effects and broader efficacy. More importantly, some cancers rapidly acquire resistance to cisplatin (2) , and compounds that can avoid this resistance will be of use clinically. Searches for other metal-based anticancer compounds led to the discovery of titanium compounds.
The two most promising titanium-based compounds, budotitane and titanocene dichloride, exhibited a greater spectrum of activity and fewer side effects than cisplatin (3) . However, they stalled in clinical trials because of complicated formulation issues and/or ineffectiveness arising from the solution instability of the compounds caused by the hydrolytic propensity of Ti(IV) (3) . The hydrolysis of Ti(IV) results in the irreversible formation of insoluble TiO 2 and the loss of anticancer activity. Progress has been made in the synthesis of derivatives of budotitane and titanocene dichloride (4) , and cytotoxicity assays have been used to gauge the potential anticancer properties of these compounds, which can be insufficient (5) . The aqueous properties of these newer Ti(IV) compounds are not typically considered during these studies, which results in compounds that suffer from the same problems as the parent compounds. Specifically, they tend to be highly waterinsoluble and/or readily labile at physiological conditions. The seemingly paradoxical nature of these compounds to exhibit their effect in cancer cells has been an important area of research.
To explain how insoluble and/or highly labile Ti(IV) compounds are cytotoxic, the serum protein transferrin (Tf) has been implicated in the complexation and delivery of these compounds. The favored hypothesis is that the compounds deliver Ti(IV) to Tf, which then transports the metal ion to cancer cells via the Fe(III) endocytotic route (Fig. S1) (6) . Evidence in support of this hypothesis is that Tf (which possesses two identical metal-binding sites) is only 39% Fe(III)-saturated (7) and can thus bind and transport other metal ions, typically hard metal ions (8) . Ti(IV) has been shown to bind with very high affinity to Tf (9, 10), even higher than Fe(III) (9) . In vivo studies have shown Ti(IV) to be endogenously bound to Tf (11) . Furthermore, Ti(IV) from titanocene dichloride rapidly binds to Tf (6) . Moreover, Ti(IV)-bound Tf (Ti 2 -Tf) is thought to specifically target cancer cells because some cancer cells express higher levels of Tf receptors (12) . Ti 2 -Tf binds with high affinity to Tf receptor 1 (TfR1) (13) , and it has also been shown to block Fe(III)-bound Tf (Fe 2 Tf) from entering a placental cancer cell line (6) . In this model, the Ti(IV) compounds play a prodrug role. Minimizing the lability of Ti(IV) compounds is thought to better facilitate delivery of Ti(IV) to Tf (14) .
Several studies, however, demonstrate that Tf may not significantly contribute to the ability of Ti(IV) to induce cell death. In one study, structurally similar titanocenes that deliver Ti(IV) to Tf at comparably fast rates and degrees of saturation were found not only to poorly induce cytotoxicity in HT-29 colon cancer cells but also to induce at different half-maximal inhibitory concentrations (IC 50 ) (15) . In more conclusive studies, the addition of Tf to cell-viability assays did not improve the cytotoxicity of different Ti(IV) compounds in several cell lines, with the exception of titanocene dichloride in some instances (16) (17) (18) (19) .
Serum albumin (SA), the most abundant serum protein, was recently proposed to participate in the anticancer property of Ti (IV) compounds by facilitating the transport of these compounds into cancer cells (Fig. S1) (13, 20) . SA's impressive ability to bind and transport different classes of ligands at multiple binding sites is currently being exploited in the design of drugs that specifically target SA or are conjugated to the protein (21) . SA has been shown to bind hard metals such as Ti(IV) in metal-chelate form (13, 20) . Binding to SA affords a mechanism by which a Ti(IV) compound, such as the titanocene moiety (22, 23) , could be delivered intact to cancer cells and directly exhibit its effect. Several hydrolysis-prone Ti(IV) compounds, including the titanocene moiety, importantly, bind to SA (13, 20, 22, 23) . However, similar to results with Tf, the addition of SA to cell-viability assays does not improve the cytotoxicity displayed by different Ti(IV) compounds (24) , except Titanocene Y (24) . Clearly, other factors are involved in the transport of, and activity exhibited by, cytotoxic Ti(IV) compounds.
Although the role of transfer proteins is not conclusive, studies suggest that the structure of Ti(IV) compounds is likely playing an important role. For many Ti(IV) compounds, the identity of their ligands is far more important to their cytotoxicity than was originally appreciated. Recently, greater emphasis has been placed on using less labile ligands in the synthesis of Ti(IV) compounds. The substitution of fluoride for chloride in several titanocene-related compounds, for instance, has dramatically improved their ability to induce cell death in HeLa S3 and Hep G2 cells (25) . The ligands also play more important roles than simply that of a hydrolysis preventative medium. The anticancer behavior of Ti(IV) compounds is likely attributable to specific features of the ligands. One study suggests that partial ligand dissociation of titanocenerelated compounds may result in ligand coordination rearrangement (26) . This rearrangement would change the overall charge of the compound from neutral to positive and may facilitate direct interaction with the DNA backbone through ionic interactions resulting in cell death (26) . Another study shows that substitutions ortho to the binding phenolato unit of salan-type ligands influences the cytotoxicity of these types of Ti(IV) compounds because of electronic and steric effects (27) . In addition, both the chirality of ligands (28) and ligand coordination to Ti(IV) (28, 29) can affect the cytotoxicity of Ti(IV) compounds.
The ligand properties that are essential for the cytotoxicity of Ti(IV) compounds are not well defined and appear to be cellspecific. A549 human lung cancer cells, which are susceptible to cisplatin, have previously been studied in Ti(IV) research, with specific focus on titanocene compounds. The parent compound titanocene dichloride does not kill A549 cells well (IC 50 > 100 μM); however, modifications of the cyclopentadienyl ring can improve the ability of titanocenes to induce A549 cell death (30) (31) (32) . The improvement in water solubility is the most probable rationale as to why certain modifications improve the potency of the compound. These studies strongly support the need to investigate ligand properties essential for Ti(IV) cytotoxicity.
Herein, we examine the ability of three Ti(IV) compounds to induce cell death in A549 cells. We attain insight into the ligand properties imperative to A549 cell death through the selection of the ligands: citrate, naphthalene-2,3-diolate ( − compound is found to be the only cytotoxic agent with potent activity comparable to cisplatin. Aqueous speciation, MS, and serum protein-interaction studies demonstrate that [TiO(HBED)] − exhibits its effect via a serum protein-independent but ligand-dependent pathway. This paper reveals the importance of the ligand in the activity of Ti(IV) compounds and demonstrates a specific approach toward the development of Ti(IV)-based anticancer therapeutics.
Results
Crystal Structure of (C 6 H 5 ) 4 
− was crystallized at pH 7.0 ( Fig. 1 ) in the presence of (C 6 H 5 ) 4 P + and DMF. The complex differs in the denticity of HBED chelation from Ti(HBED) formed at pH 3.0 (33). The increase in pH results in dissociation of one of the phenolate oxygens from Ti(IV), transforming HBED from a hexadentate to a pentadentate ligand. In place of the phenolate oxygen, which becomes protonated, is a terminal oxo ligand. The pH 7.0 compound has spectroscopic features (SI Materials and Methods) that are characteristic of other titanyl complexes (34) (35) (36) (37) (38) . Relevant crystallographic data are presented in Tables S1 and S2 . 
Reactivity of [TiO(HBED)]
− with Tf and SA. Equilibrium dialysis performed at pH 7.4 
revealed that [TiO(HBED)]
− does not deliver Ti(IV) to Tf nor does it bind to SA at micromolar concentrations. The absence of Ti(IV) content was confirmed by a Ti(IV)-based colorimetric assay and UV-visible spectra of the dialyzed protein solutions, revealing apoproteins.
Cytotoxicity Experiments. The results of all cytotoxicity experiments performed on A549 cells are listed in Table 1 . Although Ti(IV) citrate (with and without excess citrate) and Ti(naphthalene-2,3-diolate) 3 2− were inactive against the cells, [TiO(HBED)] − exhibited slightly weaker potency (Fig. S6) . Ti(IV) bound to Tf in both unhydrolyzed and hydrolyzed forms, and as a titanocene compound bound to SA, did not demonstrate any cytotoxic property. The Ti(IV) small compounds were inactive against HL-60 leukemia and UACC-62 melanoma cells. at the IC 50 . Nearly 50% cell death was confirmed by the trypan blue exclusion assay, and the dead cells were microscopically observed not to be lysed (Fig. S7) . The remaining live cells were fractionated into membrane and intracellular fractions. [TiO(HBED)] − was found to be slightly more abundant in the intracellular fraction at low-picomole amounts as determined by comparison with a 10-pmol [TiO(HBED)]
− standard (Fig. 3) .
Discussion
Three Ti(IV) compounds with distinct ligands were studied to determine what factors influence their ability to induce cell death in A549 cells. A driving factor in the selection of these ligands was the nature of their binding to Ti(IV) in aqueous solution at pH 7.4. Previous work has shown that citrate (13, 39 An aqueous speciation study performed here reveals that HBED has a high affinity for Ti(IV) (Fig. 2 ) and exists as a 1:1 metal-ligand monomeric complex over a broad pH range (3-10) at micromolar concentrations ( Fig. 2 and Fig. S3 ). At pH 7.4, partial HBED dissociation from the metal occurs, and an oxo or hydroxo ligand binds to it, as supported by electrospray MS (Fig.  S4 ). This partially hydrolyzed but highly stable species predominates at this pH. The crystal structure ( Fig. 1 and Tables S1 and S2) reveals that one of the phenolate oxygens is displaced and becomes protonated.
The bioactivity of the ligands is also of major interest because this property could play a role in governing the transport of Ti(IV) to, and possibly into, A549 cells. Citrate is an endogenous bioactive (40) molecule present at 100 μM in serum. There are wellcharacterized receptors that transport citrate into and throughout cells (40) . HBED, although not endogenous, is also bioactive. HBED is a cell-permeable molecule that is a promising candidate for iron-overload disease therapy because of its high Fe(III) affinity (41). Ti(IV) compounds of diamine-bis(phenolato) ligands, which are related to HBED but lack the carboxylate appendages, display cytotoxic properties in different cell lines in vitro (14, 17, 19, 28, (42) (43) (44) and in a mouse cancer model in vivo (35) . It is feasible that Ti(IV) compounds of citrate and HBED could use ligand-specific mechanisms for transport into cells. Naphthalene-2,3-diolate possesses no reported bioactivity.
Ligand polarity may be another critical factor controlling the transport of Ti(IV) compounds because of how it may affect interaction of the compounds with the serum proteins Tf and SA. Whereas Tf strips ligands from Ti(IV) when it binds the metal ion, SA can bind Ti(IV) compounds intact with ligands of varying polarity (6, 7) . The polarity of the ligands, coupled with their dissociation stability, may discriminate Ti(IV) binding to one protein versus the other. Previous work at pH 7.4 showed that the stability constant of Ti(naphthalene-2,3-diolate) 3 2− is so high that Tf is unable to bind the metal ion (20) . The hydrophobic compound binds with fairly high affinity to SA, however. Ti(IV) citrate (a mixture of species) is able to competitively interact with both proteins, rapidly binding as an ion to Tf and as a Ti(IV) monocitrate complex to SA, likely in a hydrophilic pocket (13) . This behavior of Ti(IV) citrate is comparable to that of titanocene dichloride, although the titanocene moiety would be expected to bind in a hydrophobic site in SA (13) .
The interaction of [TiO(HBED)] − with Tf and SA was not previously explored. At pH 7.4, Tf and SA were dialyzed against [TiO (HBED)]
− at micromolar concentrations. After dialyzing against metal-free buffer, the Ti(IV) content in the protein solutions was measured by a colorimetric assay (33) . The test revealed the absence of Ti(IV). A UV-visible scan of the solutions displayed only apoproteins and no characteristics of ligand-to-metal charge-transfer bands attributable to coordinated Ti(IV) as an ion in Tf or a metalligand complex in SA (9, 13, 20, 33). Although this result could be 
N/A, Not applicable. *Tf (30 μM) and SA (600 μM) included in the cell-viability assay.
† Ti citrate is a mixture of species.
Fig. 3. LC-MS data for [TiO(HBED)]
− in a 10-pmol standard and in the mem-
brane and intracellular fractions of A549 cells (normalized areas). [TiO(HBED)]
− is slightly more abundant in the intracellular fraction.
expected for Tf because of HBED's high affinity for Ti(IV), the lack of Ti(IV) binding was hard to predict for the SA case. An Fe(III) compound of brominated HBED binds to SA but with low affinity (45) . These findings suggest that Tf and SA will not play a role in the transport of [TiO(HBED)] − nor in the potential cytotoxicity exhibited by the compound.
The Ti(IV) compounds of citrate, naphthalene-2,3-diolate, and HBED were tested for their ability to induce cell death in A549 cells (Table 1) . Cisplatin and titanocene dichloride were included in these experiments as positive and negative controls, respectively. [TiO(HBED)]
− was the only compound to demonstrate a dose-dependent antiproliferative effect, which was also fairly potent (IC 50 = 24.6 ± 0.8 μM; Fig. S5 ) and comparable to that of cisplatin ( Table 1 ). The three compounds were also tested against the HL-60 leukemia and UACC-62 melanoma cells but demonstrated no cytotoxicity.
A549 cell-viability experiments were also performed on the ligands to distinguish any contribution to cell death made specifically by the ligands ( (46) and SA (bovine albumin ELISA kit; catalog no. 8000; Alpha Diagnostic International). These protein quantities were maintained throughout the cell-viability assays and should have been sufficient for the proteins to demonstrate an influence on the activity of the Ti(IV) complexes, especially if their role is as recyclable shuttling agents. The cytotoxicity of [TiO(HBED)]
− was examined in the presence of serum physiological levels of human Tf (30 μM) and SA (600 μM), but no increase in activity was detected (Fig. S6 and Table 1 ). Instead, the potency was slightly weakened, perhaps because of nonspecific interactions with the proteins, an observation that is in agreement with the lack of detectable specific interactions at micromolar concentrations.
Tf and SA contributions to the cytotoxicity of Ti(IV) in A549 cells was further examined to determine the impact of these proteins on other Ti(IV) compounds. At serum physiological levels, Tf and SA similarly did not improve the poor cytotoxicity of titanocene dichloride (Table 1) . We then tested preformed Ti(IV) protein compounds Ti 2 -Tf and titanocene-bound SA. Ti 2 -Tf was tested in two forms, an unhydrolyzed form where the metal center is bound by protein residue ligands and a synergistic anion (13) and a hydrolyzed form where the synergistic anion and/or a protein residue ligand is displaced by an oxo or hydroxo ligand (13, 38) . Neither Ti 2 -Tf form displayed cytotoxicity nor did titanocenebound SA (Table 1) . These results strongly suggest that Ti(IV) cytotoxicity in A549 cells is not governed by Tf-directed pathways. Without surveying a broader collection of Ti(IV) compounds, it appears that SA also does not play a major role in the mechanism of Ti(IV)-based A549 cell death.
The evidence points to ligand identity being a critical factor in A549 cell antiproliferation by Ti(IV) compounds. Preventing ligand lability is not a major component. The Ti(IV) compound of naphthalene-2,3-diolate does not readily dissociate, and yet it does not demonstrate any antiproliferative behavior. The addition of excess citrate 3− to serum physiological levels (100 μM) does not improve the cytotoxicity of the extremely labile Ti(IV) citrate. Where some degree of ligand coordination stability is important is to impede rapid binding of Ti(IV) to Tf. Both titanocene dichloride and Ti(IV) citrate rapidly deliver Ti(IV) to Tf (6, 9). In the case of Ti(IV) citrate, even in the presence of millimolar concentrations of free citrate, the exchange rate of Ti (IV) transfer to micromolar amounts of Tf is fast (9) . We have already established that Ti 2 -Tf does not exhibit any cytotoxicity. If anything, Tf is an inhibitor of Ti(IV) cytotoxicity in A549 cells.
Ligand polarity also does not play a significant positive role. HBED, when bound to Ti(IV), presents a hydrophobic periphery that is intermediate between the very hydrophobic one of naphthalene-2,3-diolate and the hydrophilic one of citrate. Although it is hard to predict exactly how ligand polarity may influence the cytotoxicity of Ti(IV) compounds, we speculate that it could affect transport of the compounds into cells. It certainly can orient binding of the compounds to either hydrophobic or hydrophilic pockets of SA and provide a selective means to favor binding to SA over Ti(IV) transfer to Tf. However, binding of Ti(IV) compounds to SA is not well understood. In some cases, the binding interactions seem to be specific, as with the compounds of naphthalene-2,3-diolate (23) and citrate (13) , although no binding sites have been identified. In others, the interactions seem to be nonspecific, as with titanocene dichloride (13) . It is also not certain whether SA can deliver − also does not bind to SA. Independent routes must be used by the compound to exhibit its cytotoxicity on A549 cells. It is highly probable that these routes are the same as those used by the metal-free ligand to penetrate cells and chelate Fe(III) in diseases related to iron overload (41) . In support of this possibility is that the charge state of [TiO(HBED)]
− is the same as that of HBED − at pH 7.4 (47) . If the mechanism of entry depends on electrostatic interactions, then both the ligand and compound could use the same pathway. (Fig. 3) ; this species is dominant at pH 3.0, which is the pH used to operate the LC. This finding is remarkable because it shows that an intact Ti(IV) compound penetrates a cell (Fig. 3) and likely uses intracellular pathways to exhibit its effect.
This work is an important demonstration of a water-soluble, solution-stable Ti(IV) compound that exhibits anticancer activity independent of serum protein interaction. Cytotoxicity tests against A549 cells reveal that the nature of the chelating ligand is crucial to the activity of [TiO(HBED)] − is active against and whether it operates by a similar mechanism of action. Future studies are also warranted to explore the anticancer properties of other bioactive ligands and HBED derivatives that form stable, well-defined solution Ti(IV) compounds, possess specific cellular target sites, and are cytotoxic. These studies will contribute to the improvement in the drug design strategies for metal-based anticancer therapeutics.
Materials and Methods
All sources for chemicals, proteins, and Ti(IV) as well as any compound synthesis are described in SI Materials and Methods.
Instrumentation. UV-visible spectra were recorded on a Cary 50 spectrophotometer (Varian). Multiwell plate absorbances were measured in a Gemini 384 plate reader. FTIR spectra (KBr pellets) were collected on a Nicolet 6700 spectrometer. Electrospray mass spectra were collected on a Waters/Micromass ZQ spectrometer. LC-MS data were collected with a NanoLC-2D (Eksigent Technologies) system coupled to a ThermoFinnigan LTQ mass spectrometer.
Spectropotentiometric Titration. Spectropotentiometric titrations were performed on 200 μM HBED and Ti(HBED). The ligand and Ti(IV) compound solutions (50 mL) contained 2.6% DMF and 0.1 M KCl. The titrations were performed under Ar from pH 3.0 to pH 10.0 and then reverse-titrated. Relative binding affinities were determined with SpecFit 3.0.36 (Spectrum Software Associates). Ligand protonation values and ligand spectra at different protonation states were used to deconvolute the spectropotentiometric data (Fig. S3) . The best fit model was determined after considering all chemically reasonable metal-ligand species and the spectroscopic characteristics of the synthesized Ti(IV) HBED compounds. All metal species are defined in terms of the total metal, ligand, and proton stoichiometry (MLH).
Cytotoxicity Studies. A549 cytotoxicity by the compounds was evaluated by using the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Cells >95% confluence [grown in 100 × 20 mm tissueculture dishes (BD Falcon)] were seeded into 96-well plates in DMEM in a volume of 100 μL at 1.0 × 10 4 cells per well on day 0. After a 24-h incubation at 37°C in a humidified atmosphere of 5% (vol/vol) CO 2 , Ti(IV) compounds, proteins, and ligands were added in a volume of 100 μL to bring the total volume of culture media in the wells to 200 μL. All solutions and dilutions of the compounds were prepared in respective buffers immediately before addition to the cultured cells to limit the possibility of precipitation upon standing. Final concentrations achieved in treated wells were 0.1-100 μM in initial screening assays and 0.1-1 mM in subsequent assays. Each compound concentration was added to four replicate wells. The plates were incubated for 3 d at 37°C in a humidified atmosphere of 5% (vol/vol) CO 2 . At 3 h before completion of the incubation time, 100 μL of medium was removed from each well, and 100 μL of MTT (Research Organics) solution (2 mg/mL in PBS) was added. The plates were kept protected from light and were then incubated at 37°C for 3 h. Subsequently, 75 μL of the solution was removed and 100 μL of 10% SDS (in 0.01 M HCl) was added to each well. The plates were returned to the incubator to allow adequate time for dissolution of the formazan crystals formed by MTT reduction. The absorbance of the solutions was measured at 570 nm, corrected for the reference wavelength at 690 nm. The IC 50 value was determined from dose-response curves. Cytotoxicity assays using HL-60 and UACC-62 cells were performed in the laboratory of Paul J. Hergenrother at the University of Illinois, Urbana, IL. 
